PUBLISHER: The Business Research Company | PRODUCT CODE: 1695308
PUBLISHER: The Business Research Company | PRODUCT CODE: 1695308
Wilms Tumor Protein (WT1) is a specific protein encoded by the WT1 gene, playing a critical role in various cellular processes, including normal kidney development during embryogenesis. Located on chromosome 11p13, the WT1 gene is expressed in several tissues, with particularly high levels in the developing kidney and the gonads. Wilms Tumor Protein plays an essential role in the normal development of the urogenital system and regulates the expression of numerous target genes.
The main types of products related to Wilms Tumor Protein include antibodies, assay kits, recombinant proteins, and others. Antibodies, also known as immunoglobulins, are proteins produced by the immune system in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Various detection methods, such as immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), western blotting, polymerase chain reaction (PCR), and others, are applied in cancer diagnosis, cancer treatment, research and development, and other applications. End users include hospitals, diagnostic laboratories, research institutes, and others.
The wilms tumor protein market research report is one of a series of new reports from The Business Research Company that provides wilms tumor protein market statistics, including wilms tumor protein industry global market size, regional shares, competitors with a wilms tumor protein market share, detailed wilms tumor protein market segments, market trends and opportunities, and any further data you may need to thrive in the wilms tumor protein industry. This wilms tumor protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The wilms tumor protein market size has grown steadily in recent years. It will grow from $3.27 billion in 2024 to $3.42 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to cancer incidence and diagnosis, rising awareness and screening programs, collaborations in cancer care.
The wilms tumor protein market size is expected to see strong growth in the next few years. It will grow to $4.35 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized medicine approaches, genomic and proteomic research advances, patient advocacy and support initiatives, regulatory support for precision medicine, integration of biomarker testing. Major trends in the forecast period include focus on early detection and screening programs, regulatory compliance in diagnostic assays, patient advocacy and awareness initiatives, integration of next-generation sequencing (ngs), global expansion of diagnostic services.
The escalating incidence of kidney cancers is poised to drive the growth of the Wilms tumor protein market in the foreseeable future. Kidney cancer, characterized by abnormal cell growth within kidney tissue, can benefit from WT1 expression analysis, especially in cases where tumors are minute or challenging to biopsy. For instance, as reported by the American Cancer Society in January 2023, approximately 81,800 new cases of kidney cancer and 14,890 deaths were recorded in 2023 in the United States. Additionally, projections by Cancer Research UK suggest an estimated 21,900 new cases of kidney cancer annually in the UK by 2038-2040. Consequently, the increasing instances of kidney cancers are expected to significantly propel the growth of the Wilms tumor protein market.
The expanding demand for personalized medicine is anticipated to fuel the growth trajectory of the Wilms tumor protein (WT1) market. Personalized medicine represents an innovative healthcare approach considering individual genetic, environmental, and lifestyle variations when designing patient-specific treatment strategies. WT1 serves as a promising target antigen for cancer immunotherapy, allowing the development of tailored immunotherapy based on its protein expression and clinical correlations for cancer patients. For example, in 2022, the Food and Drug Administration (FDA) in the United States approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities. Hence, the increasing demand for personalized medicine stands as a significant driver propelling the growth of the Wilms tumor protein (WT1) market.
Key companies in the Wilms tumor protein market are directing efforts toward developing advanced detection methodologies, such as the enzyme-linked immunosorbent assay (ELISA), to offer dependable services to their market clientele. ELISA, a highly sensitive and specific method, employs specialized enzymes that bind to antibodies in the blood, detecting Host Cell Proteins (HCPs). For instance, in February 2023, Charles River Laboratories International Inc., a US-based entity specializing in novel drug and therapeutic development, introduced an Enzyme-Linked Immunosorbent Assay (ELISA) Kit designed for the detection and quantification of residual Host Cell Proteins (HCP). This innovative HCP-ELISA kit from Charles River utilizes avian IgY antibodies as its primary detection method. These specific antibodies, exclusively produced by AVS Bio from Specific-Pathogen-Free Chicken (SPF) Eggs, form a crucial component of this novel detection system.
In December 2023, Danaher Corporation, a U.S.-based conglomerate and a leading innovator in life sciences and diagnostics, acquired Abcam plc for $5.7 billion. Through this acquisition, Danaher Corporation aims to strengthen its life sciences capabilities by utilizing Abcam's advanced antibody portfolio to accelerate drug discovery and expand its market reach. Abcam plc, a U.K.-based biotechnology company, supplies antibodies that target the Wilms Tumor Protein (WT1) for cancer research and diagnostic applications.
Major companies operating in the wilms tumor protein market report are Thermo Fisher Scientific Inc., Abbott Laboratories, Glaxosmithkline PLC, F. Hoffmann-La Roche Ltd., Otsuka Holdings Co Ltd., Agilent Technologies Inc., Illumina Inc., Sumitomo Dainippon Pharma Co Ltd., PerkinElmer Inc., ZS Genetics Inc., Tecan Trading AG, QIAGEN NV, Abcam PLC, Hamilton Company, BioLegend Inc., Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc., Sino Biological Inc., LI-COR Inc., Cell Signaling Technology Inc., Genetex Inc., Proteintech Group Inc., Zymo Research Corporation, Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Inovio Pharmaceuticals Inc., OriGene Technologies Inc., Macrogen Inc., Boster Biological Technology, Vaximm Ag, Fitzgerald Industries International
North America was the largest region in the wilms tumor protein market in 2024. The regions covered in the wilms tumor protein market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the wilms tumor protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The Wilms tumor protein market consists of revenues earned by entities by providing services such as genetic testing and counseling, cancer diagnosis, and treatment, and pediatric oncology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The wilms tumor protein market also includes sales of polymerase chain reaction (PCR) primers and probes, and research kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Wilms Tumor Protein Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on wilms tumor protein market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for wilms tumor protein ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The wilms tumor protein market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.